Immunocore appoints CMO
This article was originally published in Scrip
Immunocore, a biotechnology company developing drugs to treat cancer, viral infections and autoimmune disease, has named Christina Coughlin chief medical officer. Dr Coughlin will be responsible for providing medical and regulatory leadership to the preclinical and clinical programs for the company. Most recently, Dr Coughlin was leading two early development program at Novartis in checkpoint inhibition and PI3'kinase inhibition. Prior to this she was international project team leader at Morphotek, a monoclonal antibody company acquired by Eisai in 2007.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.